Manual / Issue 12 / On Further Review

Manual, a journal about art and its making. On Further Review. This issue uncovers narratives once central to objects’ histories but that now have been systematically obscured, inadvertently overlooked, or otherwise lost. Softcover, 96 pages. Published 2019 by the RISD Museum.(On Further Review) contributors include Anita N. Bateman, Laurie Anne Brewer, Becci Davis, Jamie Gabbarelli, Bethany Johns, Elon Cook Lee, Kevin McBride, Walker Mettling, Jessica Rosner, Suzanne Scanlan, Nell Painter, Allison Pappas, Pamela A. Parmal, Shiyanthi Thavapalan, and Nick White.https://digitalcommons.risd.edu/risdmuseum_journals/1038/thumbnail.jp

Manual / Issue 14 / Shadows

Manual, a journal about art and its making. Shadows. This anti-visibility is not the same as being invisible, rather it is the power to operate against systems of imperial domination, including the gaze. It asks: How do we force the gaze to surrender? What if explanation were off the table? By enabling a petit marronage that can be expressed in the visual and symbolic use of shadow, the gaze is challenged. This issue of Manual and the accompanying exhibition (opening at the RISD Museum Fall 2020) posit that the right to opacity de-burdens contemporary work by artists who identify as Black and/or queer and/or feminist and/or non-binary and/or OVER IT—whatever sociocultural constriction “it” signifies. Opacity extends to artists who are simply not interested in explaining themselves or offering the emotional labor that is expended for inclusion. This right says, “I have given enough.” It also legitimizes and reclaims the shadow as a place of refuge, instead of being a place from which to escape. –Anita N. Bateman The RISD Museum’s fourteenth issue of Manual shines a light on the shadow, centering the black body as a site of possibility, liberatory self-awareness, radical non-conformity, and joyful defiance. This issue serves as a companion to the exhibition Defying the Shadow. Manual 14: Shadows opens with an excerpt on the shadow from W. E. B. Du Bois’s The Souls of Black Folk, followed by an introduction by Dr. Anita N. Bateman, who elucidates: “Operating in the shadow comes with a legacy of resistance, both in spiritual and ideological forms.” Softcover, 108 pages. Published Fall/Winter 2020 by the RISD Museum. Manual 14 (Shadows) contributors include: Andrea Achi, Emanuel Admassu, Anita N. Bateman, Makeda Best, Gina Borromeo, Rashayla Marie Brown, Shuriya Davis, Akwaeke Emezi, Tayana Fincher, Melanee C. Harvey, Kate Irvin, Sade LaNay, Kelly Taylor Mitchell, Dominic Molon, Oluremi C. Onabanjo, Kevin Quashie, Matthew Shenoda, and Leslie Wilson. This issue complements the RISD Museum exhibition Defying the Shadow, curated by Dr. Anita N. Bateman.https://digitalcommons.risd.edu/risdmuseum_journals/1040/thumbnail.jp

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Reports of Conferences, Institutes, and Seminars

The Scholarly Communication Interest Group of the New England Chapter of the Association of College and Research Libraries sponsored a workshop titled “Partnering with Faculty: Scholarly Communication Conversations,” held on July 29, 2010, at the Franklin W. Olin College of Engineering in Needham, Massachusetts. Partnering with EBSCO and the North American Serials Interest Group, Mississippi State University (MSU) Libraries hosted the ninth MidSouth eResource Symposium at MSU\u27s Mitchell Memorial Library in Starkville, Mississippi, on Thursday, September 16, 2010. ITHAKA Sustainable Scholarship was a two-day meeting at the Westin Times Square, New York City, September 27–28, 2010. Finally, published herein is a summary of the NISO Webinar “It\u27s Only as Good as the Metadata: Improving OpenURL and Knowledge Base Quality,” held October 13, 2010. © 2010 Elsevier Inc

Minimally Invasive Saliva Testing to Monitor Norovirus Infection in Community Settings.

BackgroundNorovirus is a leading cause of acute gastroenteritis worldwide. Routine norovirus diagnosis requires stool collection. The goal of this study was to develop and validate a noninvasive method to diagnose norovirus to complement stool diagnostics and to facilitate studies on transmission.MethodsA multiplex immunoassay to measure salivary immunoglobulin G (IgG) responses to 5 common norovirus genotypes (GI.1, GII.2, GII.4, GII.6, and GII.17) was developed. The assay was validated using acute and convalescent saliva samples collected from Peruvian children <5 years of age with polymerase chain reaction (PCR)-diagnosed norovirus infections (n = 175) and controls (n = 32). The assay sensitivity and specificity were calculated to determine infection status based on fold rise of salivary norovirus genotype-specific IgG using norovirus genotype from stool as reference.ResultsThe salivary assay detected recent norovirus infections and correctly assigned the infecting genotype. Sensitivity was 71% and specificity was 96% across the evaluated genotypes compared to PCR-diagnosed norovirus infection.ConclusionsThis saliva-based assay will be a useful tool to monitor norovirus transmission in high-risk settings such as daycare centers or hospitals. Cross-reactivity is limited between the tested genotypes, which represent the most commonly circulating genotypes